ArticleJAMA dermatology2013
Psoriasis severity and the prevalence of major medical comorbidity: a population-based study.
Article in JAMA dermatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04410237 (Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System), which is not on this map. Cited by 209 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System: an Observational Pilot Study
Who cites it
209 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- Efficacy and safety of vitamin D supplementation on psoriasis: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis.BMC medicine · 2022Pooled it
- Venous thrombotic events in psoriasis patients: a systematic review with meta-analysis.Annals of medicine · 2021Pooled it
- National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.Journal of the American Academy of Dermatology · 2021Guideline
- National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.Journal of the American Academy of Dermatology · 2020Guideline
- Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology.Anais brasileiros de dermatologia · 2019Guideline
- The Importance of Sex Stratification in Autoimmune Disease Biomarker Research: A Systematic Review.Frontiers in immunology · 2018Pooled it
- An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies.PloS one · 2017Pooled it
- Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.American journal of human genetics · 2015Pooled it
- Trial
- Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.The British journal of dermatology · 2022Trial
- Investigation of water bonding status of normal and psoriatic skin in vivo using diffuse reflectance spectroscopy.Scientific reports · 2021Trial
- Psoriasis risk in patients with diabetic retinopathy: A nationwide population-based study.Scientific reports · 2018Trial
- Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.Circulation. Cardiovascular imaging · 2018Trial
- Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2017Trial
- Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.BMC dermatology · 2016Trial
- Global health and economic impact of expanding the WHO essential medicines list for psoriasis: a health economic modelling study.EClinicalMedicine · 2026Article
- Prevalence of Metabolic-Dysfunction-Associated Steatotic Liver Disease in Patients with Psoriasis and Psoriatic Arthritis.Diagnostics (Basel, Switzerland) · 2026Article
- Unveiling the transcriptomic landscape of coronavirus disease 2019 and psoriasis via systems biology-based analysis.The Journal of international medical research · 2026Article
- Psoriasis in the Brazilian Public Health System: A Nationwide Analysis of Healthcare Utilization and Inequalities, 2014-2024.Healthcare (Basel, Switzerland) · 2026Article
149 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
importanceDespite the growing literature on comorbidity risks in psoriasis, there remains a critical knowledge gap on the degree to which objectively measured psoriasis severity may affect the prevalence of major medical comorbidity.
objectiveTo examine the prevalence of major medical comorbidity in patients with mild, moderate, or severe psoriasis, classified objectively based on body surface area involvement, compared with that in patients without psoriasis. DESIGN, SETTING, AND
participantsPopulation-based cross-sectional study of patient data from United Kingdom-based electronic medical records; analysis included 9035 patients aged 25 to 64 years with psoriasis and 90,350 age- and practice-matched patients without psoriasis. MAIN OUTCOMES AND MEASURES: Prevalence of major medical comorbidity included in the Charlson comorbidity index.
resultsAmong patients with psoriasis, 51.8%, 35.8%, and 12.4%, respectively, had mild, moderate, or severe disease based on body surface area criteria. The mean Charlson comorbidity index was increasingly higher in patients with mild (0.375 vs 0.347), moderate (0.398 vs 0.342), or severe psoriasis (0.450 vs 0.348) (each P < .05). Psoriasis overall was associated with higher prevalence of chronic pulmonary disease (adjusted odds ratio, 1.08; 95% CI, 1.02-1.15), diabetes mellitus (1.22; 1.11-1.35), diabetes with systemic complications (1.34; 1.11-1.62), mild liver disease (1.41; 1.12-1.76), myocardial infarction (1.34; 1.07-1.69), peptic ulcer disease (1.27; 1.03-1.58), peripheral vascular disease (1.38; 1.07-1.77), renal disease (1.28; 1.11-1.48), and rheumatologic disease (2.04; 1.71-2.42). Trend analysis revealed significant associations between psoriasis severity and each of the above comorbid diseases (each P < .05). CONCLUSIONS AND RELEVANCE: The burdens of overall medical comorbidity and of specific comorbid diseases increase with increasing disease severity among patients with psoriasis. Physicians should be aware of these associations in providing comprehensive care to patients with psoriasis, especially those presenting with more severe disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.